Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
1. Xilio initiates Phase 2 trial for XTX301, a tumor-activated IL-12. 2. Promising Phase 1 data shows two partial responses in advanced solid tumors. 3. Achievement of $17.5 million milestone extends cash runway into early 2027. 4. Xilio reports strong safety profile for XTX301 with Grade 1 or 2 side effects. 5. Efarindodekin alfa (XTX301) is positioned as a significant treatment option.